vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and HeartSciences Inc. (HSCS). Click either name above to swap in a different company.
HeartSciences Inc. is the larger business by last-quarter revenue ($2.4K vs $1.9K, roughly 1.2× Aspire Biopharma Holdings, Inc.). Aspire Biopharma Holdings, Inc. runs the higher net margin — -95337.1% vs -97179.4%, a 1842.3% gap on every dollar of revenue.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
Meril Life Sciences is an Indian multinational medical device company, with headquarters in Vapi, Gujarat, India. It was founded in 2006 and is a part of the Bilakhia Group. The company is engaged in the manufacturing of vascular intervention devices, orthopedic implants, robotics, endosurgery, ENT products and in-vitro diagnostics. Meril Life Sciences operates in over 150 countries and has employed 10000 people, as of 2024.
ASBP vs HSCS — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $2.4K |
| Net Profit | $-1.9M | $-2.4M |
| Gross Margin | 45.5% | 58.3% |
| Operating Margin | -59015.8% | -85713.2% |
| Net Margin | -95337.1% | -97179.4% |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | -12.9% |
| EPS (diluted) | $-0.04 | $-0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.4K | ||
| Q3 25 | $1.9K | $1.9K | ||
| Q1 25 | — | $0 | ||
| Q1 24 | — | $14.7K | ||
| Q4 23 | — | $3.9K | ||
| Q2 23 | — | $0 | ||
| Q1 23 | — | $1.9K | ||
| Q4 22 | — | $0 |
| Q4 25 | — | $-2.4M | ||
| Q3 25 | $-1.9M | $-2.1M | ||
| Q1 25 | — | $-2.5M | ||
| Q1 24 | — | $-1.6M | ||
| Q4 23 | — | $-1.7M | ||
| Q2 23 | — | $-1.6M | ||
| Q1 23 | — | $-1.3M | ||
| Q4 22 | — | $-1.8M |
| Q4 25 | — | 58.3% | ||
| Q3 25 | 45.5% | 60.0% | ||
| Q1 25 | — | — | ||
| Q1 24 | — | 69.0% | ||
| Q4 23 | — | 61.0% | ||
| Q2 23 | — | — | ||
| Q1 23 | — | 61.0% | ||
| Q4 22 | — | — |
| Q4 25 | — | -85713.2% | ||
| Q3 25 | -59015.8% | -98637.8% | ||
| Q1 25 | — | — | ||
| Q1 24 | — | -10376.7% | ||
| Q4 23 | — | -40254.9% | ||
| Q2 23 | — | — | ||
| Q1 23 | — | -67143.7% | ||
| Q4 22 | — | — |
| Q4 25 | — | -97179.4% | ||
| Q3 25 | -95337.1% | -108157.6% | ||
| Q1 25 | — | — | ||
| Q1 24 | — | -11182.4% | ||
| Q4 23 | — | -44830.2% | ||
| Q2 23 | — | — | ||
| Q1 23 | — | -68826.4% | ||
| Q4 22 | — | — |
| Q4 25 | — | $-0.85 | ||
| Q3 25 | $-0.04 | $-1.58 | ||
| Q1 25 | — | $-2.57 | ||
| Q1 24 | — | $-3.01 | ||
| Q4 23 | — | $-15.92 | ||
| Q2 23 | — | $-79.34 | ||
| Q1 23 | — | $-0.16 | ||
| Q4 22 | — | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $2.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $4.2M |
| Total Assets | $2.4M | $6.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $2.8M | ||
| Q1 25 | — | $2.6M | ||
| Q1 24 | — | $7.1M | ||
| Q4 23 | — | $100.1K | ||
| Q2 23 | — | $1.7M | ||
| Q1 23 | — | $1.9M | ||
| Q4 22 | — | $3.1M |
| Q4 25 | — | $4.2M | ||
| Q3 25 | $-11.5M | $3.1M | ||
| Q1 25 | — | $1.8M | ||
| Q1 24 | — | $8.6M | ||
| Q4 23 | — | $-1.6M | ||
| Q2 23 | — | $230.6K | ||
| Q1 23 | — | $-257.9K | ||
| Q4 22 | — | $1.1M |
| Q4 25 | — | $6.0M | ||
| Q3 25 | $2.4M | $6.4M | ||
| Q1 25 | — | $5.7M | ||
| Q1 24 | — | $10.8M | ||
| Q4 23 | — | $2.4M | ||
| Q2 23 | — | $3.3M | ||
| Q1 23 | — | $3.5M | ||
| Q4 22 | — | $4.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-2.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.3M | ||
| Q3 25 | $-1.1M | $-2.0M | ||
| Q1 25 | — | $-1.6M | ||
| Q1 24 | — | $-2.1M | ||
| Q4 23 | — | $-988.2K | ||
| Q2 23 | — | $-1.9M | ||
| Q1 23 | — | $-1.0M | ||
| Q4 22 | — | $-1.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | $-2.1M | ||
| Q4 23 | — | $-990.1K | ||
| Q2 23 | — | $-1.9M | ||
| Q1 23 | — | $-1.0M | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | -14352.1% | ||
| Q4 23 | — | -25388.2% | ||
| Q2 23 | — | — | ||
| Q1 23 | — | -52486.8% | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | 59.8% | ||
| Q4 23 | — | 50.1% | ||
| Q2 23 | — | — | ||
| Q1 23 | — | 177.9% | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
